Beyond DNA repair: Additional functions of PARP-1 in cancer

Frontiers in Oncology

Volumn 3 NOV, Issue , 2013, Pages

  Weaver, Alice N ^a   Yang, Eddy S ^a,b,c  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; ERK signaling; Genetic transcription; Mitotic spindle; NF B; PARP inhibitors; PARP 1; Sex hormone signaling

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 8; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE SYNTHASE; PROTEIN P53; RNA POLYMERASE II; SEX HORMONE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN PROTEIN LIGASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL ENERGY; CELL PROLIFERATION; CHROMATIN STRUCTURE; DNA DAMAGE; DNA FRAGMENTATION; DNA METHYLATION; DNA REPAIR; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; M PHASE CELL CYCLE CHECKPOINT; MELANOMA; METASTASIS; MITOSIS SPINDLE; NEOPLASM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84891052763     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00290     Document Type: Article

References (111)

1. Houtgraaf JH, Versmissen J, van der Giessen WJ. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med (2006) 7(3):165-72. doi: 10.1016/j.carrev.2006.02.002
2. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst (2004) 96(1):56-67. doi:10.1093/jnci/djh005
3. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 14(23):7917-23. doi:10.1158/1078-0432.CCR-08-1223
4. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 104(5):750-5. doi:10.1038/bjc.2011.8
5. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res (2012) 18(6):1726-34. doi:10.1158/1078-0432.CCR-11-2821
6. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol (2011) 99(3):331-8. doi:10.1016/j.radonc.2011.05.084
7. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434(7035):913-7. doi:10.1038/nature03443
8. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434(7035):917-21. doi:10.1038/nature03445
9. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361(2):123-34. doi:10.1056/NEJMoa0900212
10. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (2009) 27(185):CRA501. doi:10.1016/S0140-6736(10)60892-6
11. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 12(9):852-61. doi:10.1016/S1470-2045(11)70214-5
12. Melisi D, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, et al. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin Cancer Res (2009) 15(20):6367-77. doi:10.1158/1078-0432.ccr-09-0910.
13. Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res (2012) 72(18):4796-806. doi:10.1158/0008-5472.CAN-12-1287
14. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 19(5):664-78. doi:10.1016/j.ccr.2011.04.010
15. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res (2012) 72(7):1608-13. doi:10.1158/0008-5472.CAN-11-3648
16. Byers LA, Nilsson MB, Masrorpour F, Wang J, Diao L, Bhardwaj V, et al. Investigation of PARP1 as a therapeutic target in small cell lung cancer. J Clin Oncol (2012) 30(Suppl):7096. doi:10.1371/journal.pone.0056284
17. Addioui A, Belounis A, Cournoyer S, Nyalendo C, Brito R-M, Beaunoyer M, et al. Preclinical study of a PARP inhibitor in neuroblastoma. J Clin Oncol (2012) 30(Suppl):9570.
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013
19. Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett (2002) 181(1):1-9. doi:10.1016/S0304-3835(01)00795-9
20. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer (2013) 12:86. doi:10.1186/1476-4598-12-86
21. Hassa PO, Buerki C, Lombardi C, Imhof R, Hottiger MO. Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol Chem (2003) 278(46):45145-53. doi:10.1074/jbc.M307957200
22. Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H, et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J Biol Chem (2005) 280(49):40450-64. doi:10.1074/jbc.M507553200
23. Messner S, Schuermann D, Altmeyer M, Kassner I, Schmidt D, Schar P, et al. Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function. FASEB J (2009) 23(11):3978-89. doi:10.1096/fj.09-137695
24. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell (2009) 36(3):365-78. doi:10.1016/j.molcel.2009.09.032
25. Chang WJ, Alvarez-Gonzalez R. The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J Biol Chem (2001) 276(50):47664-70. doi:10.1074/jbc.M104666200
26. Zerfaoui M, Errami Y, Naura AS, Suzuki Y, Kim H, Ju J, et al. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J Immunol (2010) 185(3):1894-902. doi:10.4049/jimmunol.1000646
27. Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene (2009) 28(6):832-42. doi:10.1038/onc.2008.439
28. Haddad M, Rhinn H, Bloquel C, Coqueran B, Szabo C, Plotkine M, et al. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol (2006) 149(1):23-30. doi:10.1038/sj.bjp.0706837
29. Jijon HB, Churchill T, Malfair D, Wessler A, Jewell LD, Parsons HG, et al. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol (2000) 279(3):G641-51.
30. Naura AS, Datta R, Hans CP, Zerfaoui M, Rezk BM, Errami Y, et al. Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. Eur Respir J (2009) 33(2):252-62. doi:10.1183/09031936.00089008
31. Korkmaz A, Kurt B, Yildirim I, Basal S, Topal T, Sadir S, et al. Effects of poly(ADP-ribose) polymerase inhibition in bladder damage caused by cyclophosphamide in rats. Exp Biol Med (Maywood) (2008) 233(3):338-43. doi:10.3181/0706-RM-151
32. Martin-Oliva D, O'Valle F, Munoz-Gamez JA, Valenzuela MT, Nunez MI, Aguilar M, et al. Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia. Oncogene (2004) 23(31):5275-83. doi:10.1038/sj.onc.1207696
33. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene (2001) 20(31):4188-97. doi:10.1038/sj.onc.1204535
34. Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev (2011) 25(12):1245-61. doi:10.1101/gad.625811
35. Cao Y, Luo JL, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A (2007) 104(40):15852-7. doi:10.1073/pnas.0706728104
36. Wesierska-Gadek J, Ranftler C, Schmid G. Physiological ageing: role of p53 and PARP-1 tumor suppressors in the regulation of terminal senescence. J Physiol Pharmacol (2005) 56(Suppl 2):77-88.
37. Yuan K, Sun Y, Zhou T, McDonald JM, Chen Y. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res (2013) 19(17):4750-9. doi:10.1158/1078-0432.CCR-13-0516
38. Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal (2011) 4(167):ra20. doi:10.1126/scisignal.2000902
39. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis (2002) 7(4):321-8. doi:10.1023/A:1016119328968
40. Ivana Scovassi A, Diederich M. Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem Pharmacol (2004) 68(6):1041-7. doi:10.1016/j.bcp.2004.04.023
41. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME. Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem (1998) 273(22):13703-12. doi:10.1074/jbc.273.22.13703
42. Racz I, Tory K, Gallyas F Jr, Berente Z, Osz E, Jaszlits L, et al. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol (2002) 63(6):1099-111. doi:10.1016/S0006-2952(01)00935-2
43. Dalaklioglu S, Sahin P, Ordueri EG, Celik-Ozenci C, Tasatargil A. Potential role of poly(ADP-ribose) polymerase (PARP) activation in methotrexate-induced nephrotoxicity and tubular apoptosis. Int J Toxicol (2012) 31(5):430-40. doi:10.1177/1091581812457430
44. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L, et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res (2001) 61(10):3908-12.
45. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci (2004) 95(2):176-80. doi:10.1111/j.1349-7006.2004.tb03200.x
46. Racz B, Hanto K, Tapodi A, Solti I, Kalman N, Jakus P, et al. Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation. Free Radic Biol Med (2010) 49(12):1978-88. doi:10.1016/j.freeradbiomed.2010.09.026
47. Szanto A, Hellebrand EE, Bognar Z, Tucsek Z, Szabo A, Gallyas F Jr, et al. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol (2009) 77(8):1348-57. doi:10.1016/j.bcp.2009.01.008
48. Zhang S, Lin Y, Kim YS, Hande MP, Liu ZG, Shen HM. c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose) polymerase-1 activation. Cell Death Differ (2007) 14(5):1001-10. doi:10.1038/sj.cdd.4402088
49. Virag L, Robaszkiewicz A, Vargas JM, Javier Oliver F. Poly(ADP-ribose) signaling in cell death. Mol Aspects Med (2013) 34(6):1153-67. doi:10.1016/j.mam.2013.01.007
50. Ethier C, Tardif M, Arul L, Poirier GG. PARP-1 modulation of mTOR signaling in response to a DNA alkylating agent. PLoS One (2012) 7(10):e47978. doi:10.1371/journal.pone.0047978
51. Wang S, Wang H, Davis BC, Liang J, Cui R, Chen SJ, et al. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. Biochem Biophys Res Commun (2011) 412(2):379-84. doi:10.1016/j.bbrc.2011.07.107
52. Sarszegi Z, Bognar E, Gaszner B, Konyi A, Gallyas F Jr, Sumegi B, et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem (2012) 365(1-2):129-37. doi:10.1007/s11010-012-1252-8
53. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem (2000) 79(3):355-69. doi:10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0
54. Kandala PK, Wright SE, Srivastava SK. Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther (2012) 341(1):24-32. doi:10.1124/jpet.111.188706
55. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol (2012) 83(3):385-94. doi:10.1016/j.bcp.2011.11.008
56. Kohno M, Tanimura S, Ozaki K. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol Pharm Bull (2011) 34(12):1781-4. doi:10.1248/bpb.34.1781
57. Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, Klein R, et al. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell (2007) 25(2):297-308. doi:10.1016/j.molcel.2006.12.012
58. Pyriochou A, Olah G, Deitch EA, Szabo C, Papapetropoulos A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med (2008) 22(1):113-8.
59. Lacal PM, Tentori L, Muzi A, Ruffini F, Dorio AS, Xu W, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Int J Oncol (2009) 34(3):861-72. doi:10.3892/ijo_00000213
60. Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, et al. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur J Cancer (2008) 44(9):1302-14. doi:10.1016/j.ejca.2008.03.019
61. Martin-Oliva D, Aguilar-Quesada R, O'Valle F, Munoz-Gamez JA, Martinez-Romero R, Garcia Del Moral R, et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res (2006) 66(11):5744-56. doi:10.1158/0008-5472.CAN-05-3050
62. Rajesh M, Mukhopadhyay P, Godlewski G, Batkai S, Hasko G, Liaudet L, et al. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun (2006) 350(4):1056-62. doi:10.1016/j.bbrc.2006.09.160
63. Rodriguez MI, Peralta-Leal A, O'Valle F, Rodriguez-Vargas JM, Gonzalez-Flores A, Majuelos-Melguizo J, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet (2013) 9(6):e1003531. doi:10.1371/journal.pgen.1003531
64. Kerr AHJ, James JA, Smith MA, Willson C, Court EL, Smith JG. An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia. Ann N Y Acad Sci (2003) 1010(1):86-9. doi:10.1196/annals.1299.013
65. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 13(5):1576-83. doi:10.1158/1078-0432.CCR-06-1150
66. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood (2007) 110(5):1656-63. doi:10.1182/blood-2007-03-081240
67. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov (2013) 3(7):742-50. doi:10.1158/2159-8290.CD-13-0070
68. Lee P, Wallace E, Yeh T, Poch G, Litwiler K, Pheneger T, et al. ARRY-142886, a potent and selective MEK inhibitor: III) efficacy in murine xenograft models correlates with decreased ERK phosphorylation. Proc Am Assoc Cancer Res (2004) 45:3890.
69. Chang P, Jacobson MK, Mitchison TJ. Poly(ADP-ribose) is required for spindle assembly and structure. Nature (2004) 432(7017):645-9. doi:10.1038/nature03061
70. Saxena A, Saffery R, Wong LH, Kalitsis P, Choo KH. Centromere proteins cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated. J Biol Chem (2002) 277(30):26921-6. doi:10.1074/jbc.M200620200
71. Kanai M, Tong WM, Sugihara E, Wang ZQ, Fukasawa K, Miwa M. Involvement of poly(ADP-ribose) polymerase 1 and poly(ADP-ribosyl)ation in regulation of centrosome function. Mol Cell Biol (2003) 23(7):2451-62. doi:10.1128/MCB.23.7.2451-2462.2003
72. Yang F, Baumann C, De La Fuente R. Persistence of histone H2AX phosphorylation after meiotic chromosome synapsis and abnormal centromere cohesion in poly (ADP-ribose) polymerase (Parp-1) null oocytes. Dev Biol (2009) 331(2):326-38. doi:10.1016/j.ydbio.2009.05.550
73. Halappanavar SS, Shah GM. Defective control of mitotic and post-mitotic checkpoints in poly(ADP-ribose) polymerase-1(-/-) fibroblasts after mitotic spindle disruption. Cell Cycle (2004) 3(3):335-42. doi:10.4161/cc.3.3.670
74. Tong WM, Yang YG, Cao WH, Galendo D, Frappart L, Shen Y, et al. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene (2007) 26(26):3857-67. doi:10.1038/sj.onc.1210156
75. Kashima L, Idogawa M, Mita H, Shitashige M, Yamada T, Ogi K, et al. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. J Biol Chem (2012) 287(16):12975-84. doi:10.1074/jbc.M111.321828
76. Ogino H, Nozaki T, Gunji A, Maeda M, Suzuki H, Ohta T, et al. Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics (2007) 8:41. doi:10.1186/1471-2164-8-41
77. Quiles-Perez R, Munoz-Gamez JA, Ruiz-Extremera A, O'Valle F, Sanjuan-Nunez L, Martin-Alvarez AB, et al. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology (2010) 51(1):255-66. doi:10.1002/hep.23249
78. Kotova E, Lodhi N, Jarnik M, Pinnola AD, Ji Y, Tulin AV. Drosophila histone H2A variant (H2Av) controls poly(ADP-ribose) polymerase 1 (PARP1) activation in chromatin. Proc Natl Acad Sci U S A (2011) 108(15):6205-10. doi:10.1073/pnas.1019644108
79. Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL. NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell (2004) 119(6):803-14. doi:10.1016/j.cell.2004.11.002
80. Hang CT, Yang J, Han P, Cheng HL, Shang C, Ashley E, et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature (2010) 466(7302):62-7. doi:10.1038/nature09130
81. Poirier GG, de Murcia G, Jongstra-Bilen J, Niedergang C, Mandel P. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci U S A (1982) 79(11):3423-7. doi:10.1073/pnas.79.11.3423
82. Krishnakumar R, Kraus WL. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell (2010) 39(5):736-49. doi:10.1016/j.molcel.2010.08.014
83. Kraus WL, Lis JT. PARP goes transcription. Cell (2003) 113(6):677-83. doi:10.1016/S0092-8674(03)00433-1
84. Frizzell KM, Gamble MJ, Berrocal JG, Zhang T, Krishnakumar R, Cen Y, et al. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J Biol Chem (2009) 284(49):33926-38. doi:10.1074/jbc.M109.023879
85. Reale A, Matteis GD, Galleazzi G, Zampieri M, Caiafa P. Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene (2005) 24(1):13-9. doi:10.1038/sj.onc.1208005
86. Yu W, Ginjala V, Pant V, Chernukhin I, Whitehead J, Docquier F, et al. Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation. Nat Genet (2004) 36(10):1105-10. doi:10.1038/ng1426
87. Ong CT, Van Bortle K, Ramos E, Corces VG. Poly(ADP-ribosyl)ation regulates insulator function and intrachromosomal interactions in Drosophila. Cell (2013) 155(1):148-59. doi:10.1016/j.cell.2013.08.052
88. Witcher M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell (2009) 34(3):271-84. doi:10.1016/j.molcel.2009.04.001
89. Farrar D, Rai S, Chernukhin I, Jagodic M, Ito Y, Yammine S, et al. Mutational analysis of the poly(ADP-ribosyl)ation sites of the transcription factor CTCF provides an insight into the mechanism of its regulation by poly(ADP-ribosyl)ation. Mol Cell Biol (2010) 30(5):1199-216. doi:10.1128/MCB.00827-09
90. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer (2001) 91(2):205-12. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2
91. Zampieri M, Passananti C, Calabrese R, Perilli M, Corbi N, De Cave F, et al. Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity. PLoS One (2009) 4(3):e4717. doi:10.1371/journal.pone.0004717
92. Zampieri M, Guastafierro T, Calabrese R, Ciccarone F, Bacalini MG, Reale A, et al. ADP-ribose polymers localized on Ctcf-Parp1-Dnmt1 complex prevent methylation of Ctcf target sites. Biochem J (2012) 441(2):645-52. doi:10.1042/BJ20111417
93. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 97(20):1498-506. doi:10.1093/jnci/dji311
94. Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol (2007) 14(6):548-55. doi:10.1038/nsmb1248
95. Zobeck KL, Buckley MS, Zipfel WR, Lis JT. Recruitment timing and dynamics of transcription factors at the Hsp70 loci in living cells. Mol Cell (2010) 40(6):965-75. doi:10.1016/j.molcel.2010.11.022
96. Lavarone E, Puppin C, Passon N, Filetti S, Russo D, Damante G. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines. Mol Cell Endocrinol (2013) 365(1):1-10. doi:10.1016/j.mce.2012.08.019
97. Ju BG, Solum D, Song EJ, Lee KJ, Rose DW, Glass CK, et al. Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway. Cell (2004) 119(6):815-29. doi:10.1016/j.cell.2004.11.017
98. Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H, Tempst P, et al. PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell (2005) 18(1):83-96. doi:10.1016/j.molcel.2005.02.034
99. Nirodi C, NagDas S, Gygi SP, Olson G, Aebersold R, Richmond A. A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J Biol Chem (2001) 276(12):9366-74. doi:10.1074/jbc.M009897200
100. Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Samara R, Espinoza LA, Hassa PO, et al. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase. Oncogene (2003) 22(52):8460-71. doi:10.1038/sj.onc.1206897
101. Kannan P, Yu Y, Wankhade S, Tainsky MA. PolyADP-ribose polymerase is a coactivator for AP-2-mediated transcriptional activation. Nucleic Acids Res (1999) 27(3):866-74. doi:10.1093/nar/27.3.866
102. Zeng Y-X, Somasundaram K, El-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet (1997) 15(1):78-82. doi:10.1038/ng0197-78
103. Lin Y, Tang X, Zhu Y, Shu T, Han X. Identification of PARP-1 as one of the transcription factors binding to the repressor element in the promoter region of COX-2. Arch Biochem Biophys (2011) 505(1):123-9. doi:10.1016/j.abb.2010.09.016
104. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 11(11):761-74. doi:10.1038/nrc3106
105. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol (2010) 28(26):4038-44. doi:10.1200/JCO.2009.27.4290
106. Zhang F, Wang Y, Wang L, Luo X, Huang K, Wang C, et al. Poly(ADP-ribose) polymerase 1 is a key regulator of estrogen receptor alpha-dependent gene transcription. J Biol Chem (2013) 288(16):11348-57. doi:10.1074/jbc.M112.429134
107. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science (2006) 312(5781):1798-802. doi:10.1126/science.1127196
108. Wright RH, Castellano G, Bonet J, Le Dily F, Font-Mateu J, Ballare C, et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev (2012) 26(17):1972-83. doi:10.1101/gad.193193.112
109. Ghabreau L, Roux JP, Frappart PO, Mathevet P, Patricot LM, Mokni M, et al. Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. Int J Cancer (2004) 109(3):317-21. doi:10.1002/ijc.11731
110. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 2(12):1134-49. doi:10.1158/2159-8290.CD-12-0120
111. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 451(7182):1111-5. doi:10.1038/nature06548